Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1984 1
1986 1
1987 3
1988 4
1989 4
1990 2
1991 4
1992 8
1993 2
1994 1
1996 1
1997 5
1998 2
1999 4
2000 5
2001 13
2002 8
2003 11
2004 9
2005 13
2006 12
2007 18
2008 15
2009 18
2010 22
2011 10
2012 12
2013 12
2014 11
2015 7
2016 10
2017 9
2018 7
2019 6
2020 4
2021 2
2022 1
2023 3
2024 1
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

256 results

Results by year

Filters applied: . Clear all
Page 1
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC.
Socinski MA, Jotte RM, Cappuzzo F, Orlandi F, Stroyakovskiy D, Nogami N, Rodríguez-Abreu D, Moro-Sibilot D, Thomas CA, Barlesi F, Finley G, Kelsch C, Lee A, Coleman S, Deng Y, Shen Y, Kowanetz M, Lopez-Chavez A, Sandler A, Reck M; IMpower150 Study Group. Socinski MA, et al. N Engl J Med. 2018 Jun 14;378(24):2288-2301. doi: 10.1056/NEJMoa1716948. Epub 2018 Jun 4. N Engl J Med. 2018. PMID: 29863955 Free article. Clinical Trial.
Adjuvant trastuzumab in HER2-positive breast cancer.
Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Press M, Mackey J, Glaspy J, Chan A, Pawlicki M, Pinter T, Valero V, Liu MC, Sauter G, von Minckwitz G, Visco F, Bee V, Buyse M, Bendahmane B, Tabah-Fisch I, Lindsay MA, Riva A, Crown J; Breast Cancer International Research Group. Slamon D, et al. N Engl J Med. 2011 Oct 6;365(14):1273-83. doi: 10.1056/NEJMoa0910383. N Engl J Med. 2011. PMID: 21991949 Free PMC article. Clinical Trial.
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Wang-Gillam A, Li CP, Bodoky G, Dean A, Shan YS, Jameson G, Macarulla T, Lee KH, Cunningham D, Blanc JF, Hubner RA, Chiu CF, Schwartsmann G, Siveke JT, Braiteh F, Moyo V, Belanger B, Dhindsa N, Bayever E, Von Hoff DD, Chen LT; NAPOLI-1 Study Group. Wang-Gillam A, et al. Among authors: schwartsmann g. Lancet. 2016 Feb 6;387(10018):545-557. doi: 10.1016/S0140-6736(15)00986-1. Epub 2015 Nov 29. Lancet. 2016. PMID: 26615328 Clinical Trial.
Vinca alkaloids.
Schwartsmann G, Bender RA. Schwartsmann G, et al. Cancer Chemother Biol Response Modif. 1988;10:50-6. Cancer Chemother Biol Response Modif. 1988. PMID: 3079397 Review. No abstract available.
Does metformin reduce the risk of cancer in obesity and diabetes? A systematic review and meta-analysis.
Mesquita LA, Spiazzi BF, Piccoli GF, Nogara DA, da Natividade GR, Garbin HI, Wayerbacher LF, Wiercinski VM, Baggio VA, Zingano CP, Schwartsmann G, Lopes G, Petrie JR, Colpani V, Gerchman F. Mesquita LA, et al. Among authors: schwartsmann g. Diabetes Obes Metab. 2024 May;26(5):1929-1940. doi: 10.1111/dom.15509. Epub 2024 Feb 23. Diabetes Obes Metab. 2024. PMID: 38389430
Pharmacokinetic and Pharmacogenetic Markers of Irinotecan Toxicity.
Hahn RZ, Antunes MV, Verza SG, Perassolo MS, Suyenaga ES, Schwartsmann G, Linden R. Hahn RZ, et al. Among authors: schwartsmann g. Curr Med Chem. 2019;26(12):2085-2107. doi: 10.2174/0929867325666180622141101. Curr Med Chem. 2019. PMID: 29932028 Review.
Bombesin receptor regulation of emotional memory.
Roesler R, Kent P, Schroder N, Schwartsmann G, Merali Z. Roesler R, et al. Among authors: schwartsmann g. Rev Neurosci. 2012;23(5-6):571-86. doi: 10.1515/revneuro-2012-0046. Rev Neurosci. 2012. PMID: 23096238 Review.
BDNF/TrkB signaling as an anti-tumor target.
Roesler R, de Farias CB, Abujamra AL, Brunetto AL, Schwartsmann G. Roesler R, et al. Among authors: schwartsmann g. Expert Rev Anticancer Ther. 2011 Oct;11(10):1473-5. doi: 10.1586/era.11.150. Expert Rev Anticancer Ther. 2011. PMID: 21999118 No abstract available.
Natural products in anticancer therapy.
da Rocha AB, Lopes RM, Schwartsmann G. da Rocha AB, et al. Among authors: schwartsmann g. Curr Opin Pharmacol. 2001 Aug;1(4):364-9. doi: 10.1016/s1471-4892(01)00063-7. Curr Opin Pharmacol. 2001. PMID: 11710734 Review.
256 results